Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $72
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $140 to $72.
Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $140 to $72.